Combined photodynamic therapy and intravitreal triamcinolone for choroidal neovascularization secondary to punctate inner choroidopathy or of idiopathic origin: One-year results of a prospective series

Retina

Volumn 28, Issue 1, 2008, Pages 71-80

  Chan, Wai Man ^a,b   Lai, Timothy Y Y ^a   Lau, Teresa T Y ^b   Lee, Vincent Y W ^b   Liu, David T L ^b   Lam, Dennis S C ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Choroidal neovascularization; Idiopathic; Photodynamic therapy; Punctate inner choroidopathy; Triamcinolone acetonide

Indexed keywords

ANTIGLAUCOMA AGENT; LEVOFLOXACIN; LIDOCAINE; LOCAL ANESTHETIC AGENT; POVIDONE IODINE; STEROID; TRIAMCINOLONE ACETONIDE; VERTEPORFIN;

ADULT; ARTICLE; CHOROID DISEASE; CLINICAL ARTICLE; DIODE LASER; DRUG EFFICACY; DRUG SAFETY; ENDOPHTHALMITIS; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; IDIOPATHIC DISEASE; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MALE; OPEN STUDY; PHOTODYNAMIC THERAPY; PHOTOSENSITIVITY; PROSPECTIVE STUDY; RETINA DETACHMENT; SIDE EFFECT; STEROID THERAPY; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL IMPAIRMENT;

ADOLESCENT; ADULT; CHOROID DISEASES; CHOROIDAL NEOVASCULARIZATION; DRUG THERAPY, COMBINATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; GLUCOCORTICOIDS; HUMANS; INJECTIONS; MALE; MIDDLE AGED; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; TRIAMCINOLONE ACETONIDE; VISUAL ACUITY; VITREOUS BODY;

EID: 38049129118     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e31815e9339     Document Type: Article

References (41)

1. Green WR, Wilson DJ. Choroidal neovascularization. Ophthalmology 1986;93:1169-1176.
2. Grossniklaus HE, Green WR. Choroidal neovascularization. Am J Ophthalmol 2004;137:496-503.
3. Cohen SY, Laroche A, Leguen Y, et al. Etiology of choroidal neovascularization in young patients. Ophthalmology 1996;103:1241-1244.
4. Ho AC, Yannuzzi LA, Pisicano K, et al. The natural history of idiopathic subfoveal choroidal neovascularization. Ophthalmology 1995;102:782-789.
5. Lindblom B, Andersson T. The prognosis of idiopathic choroidal neovascularization in persons younger than 50 years of age. Ophthalmology 1998;105:1816-1820.
6. Spaide RF. Choroidal neovascularization in younger patients. Curr Opin Ophthalmol 1999;10:177-181.
7. Macular Photocoagulation Study Group. Argon laser photocoagulation for idiopathic neovascularization. Results of a randomized clinical trial. Arch Ophthalmol 1983;101:1358-1361.
8. Lit ES, Kim RY, Damico DJ. Surgical removal of subfoveal choroidal neovascularization without removal of posterior hyaloid: a consecutive series in younger patients. Retina 2001;21:317-323.
9. Fujii GY, Humayun MS, Pieramici DJ, et al. Initial experience of inferior limited macular translocation for subfoveal choroidal neovascularization resulting from causes other than age-related macular degeneration. Am J Ophthalmol 2001;131:90-100.
10. Spaide RF, Martin ML, Slakter J, et al. Treatment of idiopathic subfoveal choroidal neovascular lesions using photodynamic therapy with verteporfin. Am J Ophthalmol 2002;134:62-68.
11. Chan WM, Lam DS, Wong TH, et al. Photodynamic therapy with verteporfin for subfoveal idiopathic choroidal neovascularization: one-year results from a prospective case series. Ophthalmology 2003;110:2395-2402.
12. Spaide RF, Freund KB, Slakter J, Sorenson J, Yannuzzi LA, Fisher Y. Treatment of subfoveal choroidal neovascularization associated with multifocal choroiditis and panuveitis with photodynamic therapy. Retina 2002;22:545-549.
13. Rogers AH, Duker JS, Nichols N, Baker BJ. Photodynamic therapy of idiopathic and inflammatory choroidal neovascularization in young adults. Ophthalmology 2003;110:1315-1320.
14. Yoo MH, Boo HD, Kim HK. Result of photodynamic therapy for idiopathic subfoveal choroidal neovascularization. Kor J Ophthalmol 2005;19:264-268.
15. Wachtlin J, Heimann H, Behme T, et al. Long-term results after photodynamic therapy with verteporfin for choroidal neovascularizations secondary to inflammatory chorioretinal diseases. Graefes Arch Clin Exp Ophthalmol 2003;241:899-906.
16. Postelmans L, Pasteels B, Coquelet P, et al. Photodynamic therapy for subfoveal classic choroidal neovascularization related to punctate inner choroidopathy (PIC) or presumed ocular histoplasmosis-like syndrome (POHS-like). Ocul Immunol Inflamm 2005;13:361-366.
17. Leslie T, Lois N, Christopoulou D, et al. Photodynamic therapy for inflammatory choroidal neovascularisation unresponsive to immunosuppression. Br J Ophthalmol 2005;89:147-150.
18. Ruiz-Moreno JM, Montero JA, Arias L, et al. Photodynamic therapy in subfoveal and juxtafoveal idiopathic and postinflammatory choroidal neovascularization. Acta Ophthalmol Scand 2006;84:743-748.
19. Sickenberg M, Schmidt-Erfurth U, Miller JW, et al. A preliminary study of photodynamic therapy using verteporfin for choroidal neovascularization in pathologic myopia, ocular histoplasmosis syndrome, angioid streaks and idiopathic causes. Arch Ophthalmol 2000;118:327-336.
20. Coco RM, de Souza CF, Sanabria MR. Photodynamic therapy for subfoveal and juxtafoveal choroidal neovascularization associated with punctate inner choroidopathy. Ocul Immunol Inflamm 2007;15:27-29.
21. Flower RW, von Kerczek C, Zhu L, et al. Theoretical investigation of the role of choriocapillaris blood flow in the treatment of subfoveal choroidal neovascularization associated with age-related macular degeneration. Am J Ophthalmol 2001;132:85-93.
22. Moshfeghi DM, Kaiser PK, Grossniklaus HE, et al. Clinicopathologic study after submacular removal of choroidal neovascular membranes treated with verteporfin ocular photodynamic therapy. Am J Ophthalmol 2003;135:343-350.
23. Wachtlin J, Behme T, Heimann H, et al. Concentric retinal pigment epithelium atrophy after a single photodynamic therapy. Graefes Arch Clin Exp Ophthalmol 2003;241:518-521.
24. Spaide RF, Sorenson J, Maranan L, et al. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2005;112:301-304.
25. Spaide RF, Sorenson J, Maranan L, et al. Combined photodynamic therapy and intravitreal triamcinolone for nonsubfoveal choroidal neovascularization. Retina 2005;25:685-690.
26. Chan WM, Lai TY, Wong AL, et al. Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of subfoveal choroidal neovascularisation in age related macular degeneration: a comparative study. Br J Ophthalmol 2006;90:337-341.
27. Augustin AJ, Schmidt-Erfurth U. Verteporfin and intravitreal triamcinolone acetonide combination therapy for occult choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006;141:638-645.
28. Rechtman E, Danis RP, Pratt LM, et al. Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularisation in age related macular degeneration. Br J Ophthalmol 2004;88:344-347.
29. Nicolo M, Ghiglione D, Lai S, et al. Occult with no classic choroidal neovascularization secondary to age-related macular degeneration treated by intravitreal triamcinolone and photodynamic therapy with verteporfin. Retina 2006;26:58-64.
30. Holladay JT. Proper method for calculating average visual acuity. J Refract Surg 1997;13:388-391.
31. Treatment of Age-related macular degeneration with Photodynamic therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report. Arch Ophthalmol 1999;117:1329-1345.
32. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial inkling lesions with occult with no classic choroidal neovascularization - verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2001;131:541-560.
33. Bressler SB, Bressler NM, Fine SL, et al. Natural course of choroidal neovascular membranes within the foveal avascular zone in senile macular degeneration. Am J Ophthalmol 1982;93:157-163.
34. Brown J Jr, Folk JC, Reddy CV, et al. Visual prognosis of multifocal choroiditis, punctate inner choroidopathy, and the diffuse subretinal fibrosis syndrome. Ophthalmology 1996;103:1100-1105.
35. Giovannini A, Neri P, Mercanti L, Brue C. Photodynamic treatment versus photodynamic treatment associated with systemic steroids for idiopathic choroidal neovascularisation. Br J Ophthalmol 2007;91:620-623.
36. Flaxel CJ, Owens SL, Mulholland B, et al. The use of corticosteroids for choroidal neovascularization in young patients. Eye 1998;12:266-272.
37. Ishibashi T, Miki K, Sorgente N, et al. Effects of intravitreal administration of steroids on experimental subretinal neovascularization in subhuman primate. Arch Ophthalmol 1985;103:708-711.
38. Matsuda S, Gomi F, Oshima Y, et al. Vascular endothelial growth factor reduced and connective tissue growth factor induced by triamcinolone in ARPE 19 cells under oxidative stress. Invest Ophthalmol Vis Sci 2005;46:1062-1068.
39. Fong KC, Thomas D, Amin K, Inzerillo D, Horgan SE. Photodynamic therapy combined with systemic corticosteroids for choroidal neovascularisation secondary to punctate inner choroidopathy. Eye 2007 Jan 19 [Epub ahead of print].
40. Azab M, Boyer DS, Bressler NM, et al. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration : 2-year results of a randomized clinical trial. Arch Ophthalmol 2005;123:448-457.
41. Hahn R, Sacu S, Michels S, et al. Intravitreal bevacizumab versus verteporfin and intravitreal triamcinolone acetonide in patients with neovascular age-related macular degeneration. Ophthalmologe 2007;104:588-593.